Uncategorized – Page 63

RFK Jr. Defends HHS Staff Cuts and Reorganization at House and Senate Hearings

4 months ago talkbio0Tagged Budgets, CHARGE Syndrome, Congress (U.S. Legislature), health coverage, HELP Committee, House Appropriations Committee, Medicaid, reorganization, RFK Jr., Senate, Staff

RFK Jr.; HHS; staff cuts; reorganization; Congress; House Appropriations Committee; Senate HELP Committee; budget cuts; Medicaid; health coverage

Organon Launches ‘Romantasy’-Inspired Nexplanon Ad Campaign

4 months ago talkbio0Tagged ad campaign, Contraceptive Implant, Contraceptive methods, fantasy-romance, Nexplanon, Organon, pharmaceutical marketing, romantasy ', women 's health

Organon; Nexplanon; romantasy; ad campaign; birth control; pharmaceutical marketing; women’s health; fantasy-romance; contraceptive implant

Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

4 months ago talkbio0Tagged AACR, Cancer of Neck, Clinical Trials, Event-Free Survival, Head, KEYNOTE-689 trial, Keytruda, locally advanced head, Merck, pembrolizumab, perioperative, recurrence prevention, Squamous cell carcinoma, United States Food and Drug Administration

Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

4 months ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

OpenAI Debuts HealthBench Dataset to Evaluate AI Models in Real-World Medical Scenarios

4 months ago talkbio0Tagged AI safety, Aortic Valve Insufficiency, Evaluation, HealthBench, healthcare benchmark, language models, medical AI, open-source dataset, OpenAI, Physicians, realistic medical scenarios, rubrics

OpenAI; HealthBench; AI healthcare benchmark; large language models; medical AI evaluation; physician rubrics; realistic medical scenarios; AI safety; open-source dataset

Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets

4 months ago talkbio0Tagged Appointments, Automobiles, biotech industry, Cell Therapy, CEO, Company Split, Galapagos, spinoff, T business

Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business

UnitedHealth Group CEO Andrew Witty Steps Down; Stephen Hemsley Returns as CEO

4 months ago talkbio0Tagged Andrew Witty, CEO, financial guidance suspension, Leadership Change, personal reasons, Stephen Hemsley, stock drop, Transition Mutation, UnitedHealth Group

UnitedHealth Group; Andrew Witty; Stephen Hemsley; CEO transition; leadership change; personal reasons; financial guidance suspension; stock drop

Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California

4 months ago talkbio0Tagged Broad Institute, Clustered Regularly Interspaced Short Palindromic Repeats, Eukaryotic Cells, Federal Circuit, Gene Modification, Intellectual Property, Legal patent, PTAB, University of California

CRISPR; patent dispute; Broad Institute; University of California; Federal Circuit; PTAB; gene editing; intellectual property; eukaryotic cells

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

4 months ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Galapagos Reconsiders Company Split After Market Developments

4 months ago talkbio0Tagged Cell Therapy, Company Split, conditions, Drug Development, Galapagos, Leadership Change, Market, strategic review

Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions